Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
J Cardiothorac Surg ; 19(1): 156, 2024 Mar 26.
Artículo en Inglés | MEDLINE | ID: mdl-38532504

RESUMEN

This is a case report of a 78-year-old male who underwent a sub-coronary aortic valve and root replacement due to valve dehiscence and aortic root pseudoaneurysm. The patient had complex anomalous coronary anatomy and had undergone a previous tissue aortic valve replacement in 2013. The patient made an uneventful recovery and was discharged from the hospital five days later. The authors suggest that the sub-coronary root replacement technique should be considered in elderly patients and patients with complex coronary anatomy.


Asunto(s)
Insuficiencia de la Válvula Aórtica , Implantación de Prótesis de Válvulas Cardíacas , Prótesis Valvulares Cardíacas , Masculino , Humanos , Anciano , Válvula Aórtica/cirugía , Insuficiencia de la Válvula Aórtica/cirugía , Aorta/cirugía , Implantación de Prótesis de Válvulas Cardíacas/métodos , Reoperación
2.
J Heart Lung Transplant ; 43(2): 241-250, 2024 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-37730188

RESUMEN

BACKGROUND: Pulmonary endarterectomy (PEA) is the guideline-recommended treatment for patients with chronic thromboembolic pulmonary hypertension (CTEPH). However, some patients develop severe cardiopulmonary compromise before surgery, intraoperatively, or early postoperatively. This may result from advanced CTEPH, reperfusion pulmonary edema, massive endobronchial bleeding, or right ventricular (RV) failure secondary to residual pulmonary hypertension. Conventional cardiorespiratory support is ineffective when these complications are severe. Since 2005, we used extracorporeal membrane oxygenation (ECMO) as a rescue therapy for this group. We review our experience with ECMO support in these patients. METHODS: This study was a retrospective analysis of patients who received perioperative ECMO for PEA from a single national center from August 2005 to July 2022. Data were prospectively collected. RESULTS: One hundred and ten patients (4.7%) had extreme cardiorespiratory compromise requiring perioperative ECMO. Nine were established on ECMO before PEA. Of those who received ECMO postoperatively, 39 were for refractory reperfusion lung injury, 20 for RV failure, 31 for endobronchial bleeding, and the remaining 11 were for "other" reasons, such as cardiopulmonary resuscitation following late tamponade and aspiration pneumonitis. Sixty-two (56.4%) were successfully weaned from ECMO. Fifty-seven patients left the hospital alive, giving a salvage rate of 51.8%. Distal disease (Jamieson Type III) and significant residual pulmonary hypertension were also predictors of mortality on ECMO support. Overall, 5- and 10-year survival in patients who were discharged alive following ECMO support was 73.9% (SE: 6.1%) and 58.2% (SE: 9.5%), respectively. CONCLUSIONS: Perioperative ECMO support has an appropriate role as rescue therapy for this group. Over 50% survived to hospital discharge. These patients had satisfactory longer-term survival.


Asunto(s)
Oxigenación por Membrana Extracorpórea , Insuficiencia Cardíaca , Hipertensión Pulmonar , Daño por Reperfusión , Humanos , Oxigenación por Membrana Extracorpórea/efectos adversos , Hipertensión Pulmonar/cirugía , Hipertensión Pulmonar/etiología , Estudios Retrospectivos , Resultado del Tratamiento , Hemorragia/etiología , Insuficiencia Cardíaca/terapia , Endarterectomía/efectos adversos , Daño por Reperfusión/complicaciones , Reino Unido/epidemiología
3.
Ann Cardiothorac Surg ; 11(2): 128-132, 2022 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-35433361

RESUMEN

Background: Pulmonary thromboendarterectomy (PTE) was first introduced to the UK 25 years ago, and the UK national service is provided by a single hospital. The aim of this work is to summarize our experience and review activity and outcomes by era at a high-volume PTE center. During this period the understanding of chronic thromboembolic pulmonary hypertension (CTEPH) increased and drug treatments and balloon angioplasty were developed. We also review our contribution to the better understanding of this surgery and CTEPH. Methods: We retrospectively reviewed all patients undergoing PTE for CTEPH at our center between Jan 1997 and Sept 2019, dividing them into four equal cohorts. Pre-operative characteristics and post-operative outcomes are described by era. A MEDLINE search was performed and original scientific clinical publications from this unit were reviewed. Their contemporary relevance and influence to the evolution of the clinical service are discussed. Results: Over this 23-year period from the commencement of our program, 2,116 consecutive PTE were performed. The mean patient age was 57.8 years (range, 11-89 years). The first 25% of our PTE were performed over 12 years whilst the most recent 25% were performed in less than three years. Over time, the average pre-operative mean pulmonary artery pressure has not changed significantly. The 30-day mortality by era quartile has progressively fallen from 12.3% to 1.9% most recently (P<0.001). Overall, one year survival exceeded 90%. 17 publications influenced our practice development during this period. Conclusions: There was a consistent increase in activity and significant improvement in outcomes between the first and last quartiles of activity studied.

4.
J Card Surg ; 35(3): 713-715, 2020 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-31999375

RESUMEN

The use of transcatheter aortic valve implantation (TAVI) in the emergency setting has not been widely reported, and TAVI is generally contraindicated in the context of endocarditis. Here we describe a patient developing acute cardiogenic shock due to prosthetic aortic valve degeneration with free-flow aortic regurgitation 8 months after receiving treatment for confirmed infective endocarditis. Due to his clinical status, he was deemed unfit for redo surgery, and he underwent salvage valve-in-valve (ViV)-TAVI. The patient made an excellent recovery. Postprocedure he was treated with a 6-week course of antibiotics, and at 18-months follow-up remains very well with no evidence of reinfection. This case may demonstrate that for selected patients with degenerative prosthetic aortic valve disease, despite a history of infective endocarditis, ViV-TAVI may be considered an alternative to redo surgery in the emergency setting.


Asunto(s)
Válvula Aórtica , Endocarditis/terapia , Prótesis Valvulares Cardíacas/efectos adversos , Falla de Prótesis , Reemplazo de la Válvula Aórtica Transcatéter/métodos , Enfermedad Aguda , Anciano , Insuficiencia de la Válvula Aórtica/cirugía , Contraindicaciones de los Procedimientos , Urgencias Médicas , Estudios de Seguimiento , Humanos , Masculino , Choque Cardiogénico/etiología , Reemplazo de la Válvula Aórtica Transcatéter/efectos adversos , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...